Latest Innovation News

MONEYME has exceeded its FY25 operating cash profit expectations by 20%, driven by robust loan book expansion and improved credit quality, while gearing up for a major credit card launch.

Livium Ltd reported a modest net profit in its battery recycling division for Q4 FY25, while securing significant new contracts and progressing lithium extraction technology development.

Dotz Nano has partnered with CarbonCapture Inc. to scale its high-performance direct air capture sorbent, while raising AU$1.2 million to fund its DotzEarth project amid ongoing funding timing challenges.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Acrux Limited has secured a decade-long licensing agreement with Servacure to commercialise its FDA-approved Dapsone 5% Gel in Saudi Arabia, marking a strategic step in its global expansion.

FlexiRoam Limited has achieved profitability in Q4 FY25, marking a significant turnaround with a positive EBITDA and net profit. Founder Jefrey Ong is appointed permanent CEO to steer the company’s next growth phase.

One Click Group Limited reported a 28% revenue increase to $1.3 million in H1 2025, launched a new $500 cash advance product, and surpassed 200,000 registered users, setting the stage for further growth.

Lithium Universe Limited has secured global rights to a breakthrough solar panel recycling technology that promises to unlock vast reserves of critical minerals, while advancing its Québec lithium refinery with robust financials and strategic partnerships.

Alexium International Group faced a tough FY25 with declining sales amid a soft US mattress market but is poised for growth in FY26 thanks to technological advances and strategic funding support.

INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.

Fluence Corporation Limited reported a positive net operating cash flow of US$5.1 million for Q2 2025, boosting its cash reserves to US$12.7 million and maintaining solid liquidity through revolving credit and loan facilities.

Nyrada reports successful completion of five cohorts in its Phase I trial of Xolatryp with no safety concerns, alongside compelling preclinical neuro- and cardioprotective data. A Phase IIa trial targeting heart attack patients is slated for early 2026.